Background: Visual analogue scales (VAS) are simple symptom assessment tools which have not been validated in interstitial lung disease (ILD). Simple measures of ILD disease burden would be valuable for non-specialist clinicians monitoring disease away from ILD specialist centres. Objective: To validate VAS to assess change in dyspnoea, cough and fatigue in ILD, and to define the minimal clinically important difference (MCID) for change in these. Methods: Patients of 64 with ILD completed VAS for dyspnoea, cough and fatigue. Baseline King's Brief ILD questionnaire (K-BILD) scores, lung function and 6-min walk test results were collected. Tests were repeated 3-6 months later, in addition to a seven-point Likert scale. The MCID was estimated using median change in VAS in patients who reported 'small but just worthwhile change' in symptoms at follow-up. Methods were repeated in a validation cohort of 31 ILD patients to confirm findings. Results: VAS scores were significantly higher for patients who reported a 'small but just worthwhile change' in symptoms vs. 'no change' or 'not worthwhile change' (P < 0.01). The MCID for VAS Dyspnoea was estimated as 22.0 mm and 14.5 mm for VAS Fatigue. These results were reproducible in the validation cohort. Results were not significant for VAS Cough. Change in VAS Dyspnoea correlated with change in K-BILD (r ¼ -0.51, P < 0.01), forced vital capacity (r ¼ -0.32, P ¼ 0.01) and 6-min walking distance (r ¼ -0.37, P ¼ 0.01). Conclusion: The VAS is valid for assessing change in dyspnoea and fatigue in ILD. The MCID is estimated as 22.0 mm for dyspnoea and 14.5 mm for fatigue. This could be used to monitor disease in settings away from ILD specialist review.
Introduction
Interstitial lung diseases (ILDs) are chronic, progressive disorders of the lung parenchyma associated with significant morbidity and mortality. 1 Despite recent advances in ILD therapies, 2 the care of a large proportion of ILD patients focuses on the management of dyspnoea, cough and fatigue. [3] [4] [5] Objective measures of lung function and exercise testing may not reflect patient experience of disease, and HRQL tools can be time consuming to complete and interpret, limiting their use. Increasingly, the model of care for patients with ILD is of shared care between a local, referring centre and a specialist ILD centre. This care may incorporate community nurses, nonspecialist physicians and other allied health professionals. Simple, quickly completed tools to assess patients' symptoms in ILD would be valuable additions to clinical assessment outside well-resourced specialist centres. 4 The visual analogue scale (VAS) is a simple tool for assessing patients' symptoms, which has been validated in asthma, 6 chronic obstructive pulmonary disease 7 and pleural disease. 8 Only one study has assessed VAS in ILD, however the sample size was small (n ¼ 27) and this did not assess change over time. 9 The aim of this study was to investigate whether VAS are valid tools for assessing change in dyspnoea, cough and fatigue in a diverse range of ILD, as encountered in a heterogeneous ILD clinic and to identify the minimal change considered worthwhile to the patient, 10 also known as the minimum clinically important difference (MCID).
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Materials and methods
Assessing validity of VAS and determining the MCID
This was a prospective observational study. Ethical approval was granted by East of Scotland Research Ethics Service and all participants provided written consent. Patients with a range of fibrotic ILDs were recruited consecutively from the Bristol ILD service at North Bristol NHS Trust from January 2016-November 2016. Inclusion criteria were: a consensus diagnosis of ILD made at the regional ILD multi-disciplinary meeting according to international criteria, 12 with fibrotic changes on computed tomography imaging of the chest, English speaking and a minimum of primary school education. Patients with co-existing pulmonary hypertension were not included. Patients completed written VAS for dyspnoea, cough and fatigue, lung function tests, a 6-min walk test distance (6 MWD) and the Kings Brief ILD (K-BILD) HRQL tool. VAS design was a 100 mm continuous, horizontal line labelled to express symptom extremes, based on existing VAS for other respiratory disease ( Figure 1) . 13 These assessments were completed with the assistance of respiratory physiologists supervising their lung function testing. At follow-up after 3-6 months, patients completed a second VAS, a seven-point Likert scale, lung function tests, 6 MWD and repeated the K-BILD tool ( Figure 1 ). Patients were shown their previous VAS scores as this has been demonstrated to increase the validity of patient reported outcomes.
14 This is an approach likewise applied in the estimation of the VAS Dyspnoea (VASD) in pleural disease. 8 VAS scores were calculated by measuring the distance in millimetres from the start of the line to the centre of the point recorded by the patient. 13 Change in VAS was calculated from the difference between VAS score at initial and follow-up visits.
In analysing results, the relative change in symptoms was explored by combining improvement and deterioration together. This resulted in four categories for analysis. Data were categorized according to Likert scale response; 'no change', 'slight change but not worthwhile', 'small but just worthwhile change' and 'large or moderate change' (Figure 1 ). The MCID was estimated using the median change in VAS in the 'small but just worthwhile change' category. Forced Vital Capacity (FVC) and 6 MWD results were selected as clinical anchors to determine the MCID. 15 These are validated measures with described MCID, used in prognostication and monitoring for ILD. [16] [17] [18] Patient-based anchors were the sevenpoint Likert scale 15, 19 and the K-BILD tool. 20 Estimates of MCID were compared to distributional methods including effect size (ES) and empirical rule effect size (ERES). 21 Distributional methods provide statistical estimates of MCID from underlying variation within the sample. 21 An ES of 0.33 has been suggested to equate to the MCID, 22 therefore ES MCID was estimated by multiplying the SD of baseline VAS score by 0.33. The ERES is based on the assumption that the mean score is half of the maximum score (in this case 100 mm), and the range of the outcome measure is 6 SDs. 21 Therefore, the ERES MCID was calculated by dividing 100 by 6. Additionally, patients estimated the change in VAS which they considered 'meaningful' to provide patient-opinion estimated MCID. Results were compared with anchor and distribution-based estimates.
Statistical analysis
Statistical analyses were performed using MiniTab17 Statistical software. 23 All patients who completed data collection at follow-up were included in the analyses. Data were assessed for normality and one way analysis of variance was used to assess for differences between groups categorized by Likert score. Moods Median test was used for non-parametric data. Median change in VAS for patients reporting a 'small but just worthwhile change' was used to calculate MCID. Correlations between change in VAS and change in FVC, diffusing capacity for carbon monoxide (DL CO ), 6 MWD and K-BILD scores were assessed using Spearman's Rank correlation coefficient. The strength of correlations were determined according to absolute values of the coefficient; large (r > 0.5), moderate (r ¼ 0.5-0.3) and small (r ¼ 0.1-0.3). 24 Any influence of symptom severity on patients' perceived change in symptoms was assessed by examining correlation between baseline VAS and subsequent change in VAS. A sample size of eight patients in the Likert category 'small but just worthwhile change' was required to give a power of 90% to detect a change in VAS scores at a P values of 0.05, calculated from the MCID and SD reported in a study of dyspnoea related to pleural disease. 8, 25 The validity of the MCID was assessed by repeating these methods in a second cohort. The estimated MCID was assessed for similarity with the initial cohort using the Mann-Whitney U test. The recruitment cohort sizes were pragmatically selected to maximize the chances of achieving this in the absence of published data in this area for ILD.
Outcomes
The primary outcome of the study was the MCID estimated from the median change in VAS for patients reporting a 'small but just worthwhile change' on the seven-point Likert scale at follow-up. Other pre-specified secondary outcomes included correlation of change in VAS with change in FVC, DL CO , 6 MWD and K-BILD, and comparison of the estimated MCID with patient-opinion and distributional methods.
Results
Validating VAS and determining the MCID
Of 131 patients recruited for this study, one was excluded due to visual impairment. Completed data were available for 95/130 (73%) of patients enrolled (2 died, 33 did not attend for follow-up during the study period). The first 64 completed data sets were assigned to the initial cohort, and subsequent 31 to the validation cohort ( Figure 2 ). The baseline characteristics of patients in both cohorts were comparable and are shown in Table 1 . Mean age in the initial cohort was 66 years, 41% were female, 97% were Caucasian and 31% had Idiopathic Pulmonary Fibrosis (IPF). Mean FVC was 83% predicted and mean DL CO was 55.7% predicted.
Overall, there were 30 patients with IPF and 67 with non-IPF fibrotic lung disease included in the analyses. There was no difference between these groups for baseline or interval change in VASD, VAS Cough (VASC) or VAS Fatigue (VASF; Supplementary Table S1 ). There was no statistically significant difference in the proportion of all respondents reporting 'small but just worthwhile change' in symptoms who had IPF when compared to the proportion of respondents with IPF in the overall cohort (38.6% vs. 30.9%, P ¼ 0.304).
Anchor-based MCID
Likert scale selections were similarly distributed for dyspnoea, fatigue and cough (Table 2 ). Most patients reported 'no change' in symptoms whilst the lowest numbers reported 'moderate or large change'. Similar numbers reported a 'small but just worthwhile change' for dyspnoea, fatigue and cough.
Median changes in VAS categorized by Likert scale response are shown in Table 2 . Median change in VAS increased as Likert response increased for all symptoms. The MCID for change in VASD was 22.0 mm, equating to a 'small but just worthwhile change' on the Likert scale. Moods median showed statistically significant differences in change in VASD between all Likert groups (P < 0.001, 95% CI, 12-35 mm; Table 2 , Figure 3A) .
The MCID for change in VASF was 14.5 mm. There were statistically significant differences for change in VASF between all Likert groups (P ¼ 0.006, 95% CI, 8-20 mm; Table 2, Figure 3B ). There were no significant between-group differences in change in VASC (P ¼ 0.061; Figure 3C ), therefore the MCID could not be determined.
Distribution-based estimates of MCID were lower than anchor-based estimates for VASD (7.7 mm-8.4 mm and 22.0 mm, respectively), but values were similar for VASF (8.4 -9.0 mm and 14.5 mm, respectively; Table 3 ). Patient-opinion and anchor-based estimates of VASD MCID were similar (20.5 mm and 22.0 mm, respectively), but patient-opinion was higher for VASF (28.0 mm and 14.5 mm; Table 3 ). Median change in VAS score for patients who reported a 'small but just worthwhile change' in symptoms on the Likert scale was used to estimate the MCID.
Correlations
Change in VASD correlated moderately with change in FVC% (r ¼ -0.319) and 6 MWD (r ¼ -0.365), but there was no correlation with change in DL CO % ( Table 4) . The correlations between change in VASF and 6 MWD were moderate (r ¼ -0.349), but insignificant for FVC% and DL CO % (Table 4) . Change in VASD, VASF and VASC all moderately correlated with K-BILD scores (r ¼ -0.363-0.506). The strongest correlation was between VASD and dyspnoea-specific K-BILD domains (r ¼ -0.557; Figure 4 ). There was no correlation between VASC and K-BILD cough domains, lung function or 6 MWD (Table 4) . There was no correlation between any VAS and age. There was no correlation between initial VASD and VASF and subsequent change in VAS (r ¼ -0.075 and r ¼ -0.184, respectively). There was moderate correlation between VASC and subsequent change in VAS (r ¼ -0.364, P < 0.01). 
Validation of the MCID
Baseline characteristics for the validation cohort of 31 patients are shown in Table 1 . Anchor-based estimates of the MCID were 26.5 mm for change in VASD and 11.0 mm for change in VASF, for the validation cohort (Table 3 ). These were not significantly different for both VASD (P ¼ 0.66, 95% CI, -19-13 mm) and VASF (P ¼ 0.77, 95% CI, -7-16 mm).
Discussion
This is the first study to demonstrate that VAS is valid tools for assessing change in dyspnoea and fatigue in ILD. This is relevant as the mechanisms of exercise limitation and dyspnoea are felt to be different in ILD to those observed in COPD and in health. 26, 27 The MCID for change in VASD is 22.0 mm and VASF is 14.5 mm. VAS are simple, quick and easy to use patientreported measures, which could have value in clinical assessment outside specialist ILD centres. The validity of VAS and their responsiveness to change were shown by correlation with validated measures of disease status.
The authors recognize that there are some limitations, including those inherent to a single centre study, therefore caution should be taken before applying these findings to other populations. Patients of 33 did not return for follow-up during the study period due to the regional status of the ILD service patient. Additionally, this work was conducted in a heterogeneous cohort, including some patients with sarcoidosis, which may have influenced the findings of the VASF. These patients all had fibrotic parenchymal disease, however and the cohort was selected to represent a pragmatic, real-world clinical spectrum reviewed in ILD centres. The grouping together of IPF, a progressive disease, with non-IPF fibrotic lung diseases has the potential to influence these results, however no statistically significant differences were seen between the VAS for these groups at baseline or on follow-up. Likewise, IPF was not overrepresented in the group of respondents reporting 'small but just worthwhile change' in symptoms at follow-up. Finally, there were 33 patients who did not complete a follow-up VAS. We cannot exclude selection bias in these results, however the MCID for VAS can be applied to those returning for follow-up to an ILD clinic as this was the population for whom follow-up was completed. This does not influence our conclusions.
The selection of clinical parameters to which to compare the VAS was based on those used routinely in this ILD centre. As such, we did not compare VASC and VASF to specific cough and fatigue questionnaires. This may limit the interpretation of our results, however the VASC did not reveal significant changes over time. The K-BILD QoL tool, while not specifically designed to assess fatigue, does give a holistic assessment of patient symptoms and as such is an appropriate comparator to the VASF and VASD.There are also limitations inherent to the use of VAS. These measures are subject to 'end of scale' bias, wherein respondents are less likely to use the extreme ends of the scale to assess their health status. Likewise, it is possible that while VAS is measured to the nearest millimetre, respondents are unable to make such fine distinctions in position along a line. This should not prevent their application as a simple tool, easily interpreted by clinicians without experience or expertise in specialist QoL tools.
Dyspnoea has been reported as the principal and most debilitating symptom in ILD, 3 30, 31 Dyspnoea is influenced by several factors in addition to the pulmonary restriction and reduced gas exchange observed in ILD, and the relationships between dyspnoea and FVC, DLCO and 6 MWD are complex. 4, 28 Previous studies have found symptom domains of quality of life assessments did not correlate with FVC% and DL CO %, 32, 33 whereas other studies have found weak but statistically significant associations. 1, 18, 34 A clinical trial in patients with IPF found significant reductions in FVC were not associated with reduced dyspnoea scores. 30 A possible explanation could be that patients with more severe disease status limit their activity levels and therefore under-report symptom deterioration. 32 This is reflected in the low mean values for VASD observed in this study (34 mm) . Our findings show VASD is also associated with validated patient-reported measures. Change in VASD score was associated with change in Likert score, demonstrating its ability to reflect patient experience. 15 Furthermore change in VASD correlated with change in K-BILD scores, consistent with previous studies which found correlations between VASD and other quality of life assessments (r ¼ -0.61). 34 Change in VASD did not correlate with change in DL CO , most likely due to low magnitude of changes in DL CO observed in this study. Finally, patientestimated MCID was similar to anchor-based methods, providing further evidence that VASD accurately reflects patient opinion. Distributional methods underestimated the MCID for VASD, consistent with a study which also compared distributional and anchor-based methods. 8 Distributional approaches have been criticized as they do not use clinical anchors and provide a purely statistical estimation of MCID based on the underlying variation within the sample. 8, 15, 35 In this study, we used the optimal approach recommended for determining the MCID, with increased emphasis on anchor methods and support provided by distributional methods and patient opinion. 15, 20 The results of our study suggest that VAS is valid for assessing change in fatigue in patients with ILD, and the estimated MCID is 14.5 mm. Median VASF score was higher for patients reporting a 'small but just worthwhile change' compared to 'no change', and median change in VASF increased in association with increased Likert scale response. Additionally, the MCID was confirmed in the validation cohort. However, there were wide and overlapping 95% CI for all groups, particularly those reporting changes, and a lack of correlation of VASF with other measures. These results are consistent with a study which found VASF was less sensitive than other scales for assessing fatigue, whereas VASD was superior. 36 There is a paucity of studies which have looked specifically at the prevalence of fatigue in ILD, although it is widely understood to be common based on quality of life studies. 5 Predictors of fatigue have been modelled for IPF but could not be identified for sarcoidosis, indicating the diverse manifestation of the symptom amongst different ILDs. 37 Although VASF has not been investigated in ILD, it has been assessed in a range of diseases including Sarcoidosis, 38 rheumatoid arthiritis 39 and cancer 40 and was validated for patients with sleep disorders. 41 VASF has also been shown to correlate with objective measures including exercise testing. However, the study populations used were small and included male athletes 36 and Chinese female students, 42 limiting their applicability to our study population.
The inclusion of both ILD and Sarcoidosis patients in the same cohort has the potential to influence the results here. We acknowledging the existence of validated measures for fatigue in Sarcoidosis, however these have all examined heterogeneous populations with this disease, not only those with fibrotic lung disease, as was performed here. The correlation observed between VASF and 6 MWD could be due to the inclusion of physical muscle weakness secondary to de-conditioning within the subjective perception of fatigue. 5 Therefore although VASF was able to detect change in fatigue, given the complexity of fatigue symptoms and the mixed results observed in this study, further research is required before VASF can be recommended for clinical use in patients with ILD.
In this study, VASC was unable to detect change in cough symptoms. Previous studies have demonstrated a lack of correlation between cough rates and lung function tests 43 and between subjective and objective measures of cough. 44, 45 Cough is a complex symptom of ILD, and there are likely to be alternative causes such as rhinitis and gastro-oesophageal reflux in the patients studied. 46 Patients have identified cough as a fundamental symptom of ILD, 47 therefore it is important to establish valid methods for its assessment. This is the first study to assess change in VASD, VASF and VASC in ILD. The longitudinal study design allowed for responsiveness of VAS to be determined, and calculated MCIDs were validated in a separate cohort. This study was performed in a busy out-patient service and demonstrates the practicality of the VAS for routine use in ILD clinics.
Conclusion
This study has shown the VAS is a valid and clinically relevant tool for assessing change in dyspnoea and fatigue in patients with ILD. These scales correlate with recognized markers of disease, including K-BILD and pulmonary physiology tests.
The MCID for change in VAS is 22.0 mm for dyspnoea and 14.5 mm for fatigue. VAS is a quick and simple tool which could be used alongside lung function tests and quality of life assessments to establish disease progression and could represent a useful adjunct to clinical assessment in non-specialist settings where more time-consuming measures are not practical.
